第 1 則更新，共 1 則最新第 1 天
NSW records 1,180 peptide-linked emergency visits amid warnings on online products
Fifteen months of NSW surveillance show a sharp rise in emergency presentations associated with peptide use. The warning concerns unapproved products—not every peptide medicine.
觀看最早的來源ABC listen
最初掌握的資訊
- 1,180Emergency presentations over fifteen months
- 5Presentations in July 2025
- More than 217Presentations in September 2026
- NSW recorded a sharp rise in emergency presentations associated with peptide use, alongside a ministerial warning about serious harm from unregulated products.
當時尚無定論
- The surveillance does not identify the products involved, their verified contents, the number of distinct patients or how many suffered lasting injury.
我們說過將關注的
- Product-specific findings, fuller surveillance definitions and patient outcomes would show more clearly what is driving the increase. No date has been announced for the next surveillance release.